Skip to content
2000
Volume 32, Issue 15
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Introduction

The progressive neurodegenerative disease known as Alzheimer's disease (AD) is typified by neuroinflammation, amyloid-beta buildup, and cognitive impairment. Current pharmacological treatments merely alleviate symptoms, despite extensive research, which underscores the need for innovative, multi-target medicines. Since apolipoprotein E4 (ApoE4) is a significant genetic risk factor linked to the development of AD, it is a potentially effective treatment target. With their neuroprotective qualities, natural substances like Ginkgolide may help treat some diseases. This study investigates Ginkgolide's potential as a multi-target treatment for AD, with a particular emphasis on how it interacts with the ApoE4 N-terminal domain.

Methods

The interaction between Ginkgolide and ApoE4 (PDB ID: 8AX8) was assessed using pharmacokinetic profiling, molecular docking, and molecular dynamics (MD) simulations. MD simulations were used to determine stability, and AutoDock Vina was used to obtain the binding affinity. To predict pharmacokinetics and toxicity, SwissADME and PkCSM were employed. The effectiveness of ginkgolide was contextualized using comparative docking with curcumin and resveratrol.

Results

Ginkgolide formed sustained hydrophobic contacts with important sites and demonstrated a substantial binding affinity (-7.1 kcal/mol) to ApoE4. MD simulations verified negligible fluctuations and complex stability over 100 ns. Pharmacokinetics showed no significant toxicity risks, good gastrointestinal absorption, and favorable blood-brain barrier permeability. In terms of binding affinity and stability, ginkgolide fared better than curcumin and resveratrol, indicating its greater therapeutic potential.

Discussion

The results indicate that ginkgolide effectively binds and stabilizes the ApoE4 N-terminal domain, supporting its potential role in modulating a key pathological factor in Alzheimer’s disease. Its superior pharmacokinetic profile and interaction dynamics compared to curcumin and resveratrol suggest a broader therapeutic relevance. These insights provide a mechanistic basis for further investigation into ginkgolide’s neuroprotective effects.

Conclusion

The results demonstrated ginkgolide as a potentially effective multi-target treatment for AD through ApoE4 regulation. It is a better option than other natural chemicals because of its potent binding affinity, stability, and pharmacokinetics. These findings highlight the value of methods in the early stages of drug discovery and the need for additional experimental support before they can be used in clinical settings.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128386836250723134001
2025-08-31
2026-03-10

  • From This Site

    /content/journals/cpd/10.2174/0113816128386836250723134001
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cpd/32/15/CPD-32-15-06.html?itemId=/content/journals/cpd/10.2174/0113816128386836250723134001&mimeType=html&fmt=ahah

References

  1. JonesD. LoweV. Graff-RadfordJ. A computational model of neurodegeneration in Alzheimer’s disease.Nat. Commun.2022131164310.1038/s41467‑022‑29047‑4 35347127
     [Google Scholar]
  2. XiaX. JiangQ. McDermottJ. HanJ.D.J. Aging and Alzheimer’s disease: Comparison and associations from molecular to system level.Aging Cell2018175e1280210.1111/acel.12802 29963744
     [Google Scholar]
  3. GulisanoW. MaugeriD. BaltronsM.A. Role of amyloid-β and tau proteins in Alzheimer’s disease: Confuting the amyloid cascade.J. Alzheimers Dis.201864s1S611S63110.3233/JAD‑179935 29865055
     [Google Scholar]
  4. DhikavV. AnandK.S. Hippocampus in health and disease: An overview.Ann. Indian Acad. Neurol.201215423924610.4103/0972‑2327.104323 23349586
     [Google Scholar]
  5. JurcăuM.C. Andronie-CioaraF.L. JurcăuA. The link between oxidative stress, mitochondrial dysfunction and neuroinflammation in the pathophysiology of Alzheimer’s disease: Therapeutic implications and future perspectives.Antioxidants20221111216710.3390/antiox11112167 36358538
     [Google Scholar]
  6. IqbalK. Grundke-IqbalI. Alzheimer’s disease, a multifactorial disorder seeking multitherapies.Alzheimers Dement.20106542042410.1016/j.jalz.2010.04.006 20813343
     [Google Scholar]
  7. RingmanJ.M. GoateA. MastersC.L. Genetic heterogeneity in Alzheimer disease and implications for treatment strategies.Curr. Neurol. Neurosci. Rep.2014141149910.1007/s11910‑014‑0499‑8 25217249
     [Google Scholar]
  8. Martínez-MartínezA.B. Torres-PerezE. DevanneyN. Del MoralR. JohnsonL.A. Arbones-MainarJ.M. Beyond the CNS: The many peripheral roles of APOE.Neurobiol. Dis.202013810480910.1016/j.nbd.2020.104809 32087284
     [Google Scholar]
  9. NingZ. LiuY. WanM. ApoE2 protects against Aβ pathology by improving neuronal mitochondrial function through ERRα signaling.Cell. Mol. Biol. Lett.20242918710.1186/s11658‑024‑00600‑x 38867189
     [Google Scholar]
  10. SteeleO.G. StuartA.C. MinkleyL. A multi-hit hypothesis for an ApoE4-dependent pathophysiological state.Eur. J. Neurosci.20225695476551510.1111/ejn.15685 35510513
     [Google Scholar]
  11. PalmerJ.M. HuentelmanM. RyanL. More than just risk for Alzheimer’s disease: APOE ε4's impact on the aging brain.Trends Neurosci.202346975076310.1016/j.tins.2023.06.003 37460334
     [Google Scholar]
  12. MoonH.J. HaroutunianV. ZhaoL. Human apolipoprotein E isoforms are differentially sialylated and the sialic acid moiety in ApoE2 attenuates ApoE2-Aβ interaction and Aβ fibrillation.Neurobiol. Dis.202216410563110.1016/j.nbd.2022.105631 35041991
     [Google Scholar]
  13. DiasD. PortugalC.C. RelvasJ. SocodatoR. From genetics to neuroinflammation: The impact of ApoE4 on microglial function in Alzheimer’s disease.Cells202514424310.3390/cells14040243 39996715
     [Google Scholar]
  14. HuangY MahleyRW Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.Neurobiol Dis201472Pt A31210.1016/j.nbd.2014.08.02525173806
     [Google Scholar]
  15. LaneR.M. FarlowM.R. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer’s disease.J. Lipid Res.200546594996810.1194/jlr.M400486‑JLR200 15716586
     [Google Scholar]
  16. NazirS. JankowskiV. BenderG. ZewingerS. RyeK.A. van der VorstE.P.C. Interaction between high-density lipoproteins and inflammation: Function matters more than concentration.Adv. Drug Deliv. Rev.20201599411910.1016/j.addr.2020.10.006 33080259
     [Google Scholar]
  17. AlkhalifaA.E. Al-GhraiybahN.F. OdumJ. ShunnarahJ.G. AustinN. KaddoumiA. Blood-brain barrier breakdown in Alzheimer’s disease: Mechanisms and targeted strategies.Int. J. Mol. Sci.202324221628810.3390/ijms242216288 38003477
     [Google Scholar]
  18. KirchnerK. GarvertL. KühnL. BonkS. GrabeH.J. Van der AuweraS. Detrimental effects of Apoe Ε4 on blood-brain barrier integrity and their potential implications on the pathogenesis of Alzheimer’s disease.Cells20231221251210.3390/cells12212512 37947590
     [Google Scholar]
  19. Serrano-PozoA. DasS. HymanB.T. APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches.Lancet Neurol.2021201688010.1016/S1474‑4422(20)30412‑9 33340485
     [Google Scholar]
  20. HusainM.A. LaurentB. PlourdeM. APOE and Alzheimer’s disease: From lipid transport to physiopathology and therapeutics.Front. Neurosci.20211563050210.3389/fnins.2021.630502 33679311
     [Google Scholar]
  21. YamazakiY. ZhaoN. CaulfieldT.R. LiuC.C. BuG. Apolipoprotein E and Alzheimer disease: Pathobiology and targeting strategies.Nat. Rev. Neurol.201915950151810.1038/s41582‑019‑0228‑7 31367008
     [Google Scholar]
  22. LiZ. ShueF. ZhaoN. ShinoharaM. BuG. APOE2: Protective mechanism and therapeutic implications for Alzheimer’s disease.Mol. Neurodegener.20201516310.1186/s13024‑020‑00413‑4 33148290
     [Google Scholar]
  23. YegambaramM. ManivannanB. BeachT. HaldenR. Role of environmental contaminants in the etiology of Alzheimer’s disease: A review.Curr. Alzheimer Res.201512211614610.2174/1567205012666150204121719 25654508
     [Google Scholar]
  24. ReichmanW.E. Current pharmacologic options for patients with Alzheimer’s disease.Ann. Gen. Hosp. Psychiatry200321110.1186/1475‑2832‑2‑1 12605726
     [Google Scholar]
  25. YiannopoulouK.G. AnastasiouA.I. ZachariouV. PelidouS.H. Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research.Biomedicines2019749710.3390/biomedicines7040097 31835422
     [Google Scholar]
  26. AndradeS. RamalhoM.J. LoureiroJ.A. PereiraM.C. Natural compounds for Alzheimer’s disease therapy: A systematic review of preclinical and clinical studies.Int. J. Mol. Sci.2019209231310.3390/ijms20092313 31083327
     [Google Scholar]
  27. LiC. WongY. The bioavailability of ginkgolides in Ginkgo biloba extracts.Planta Med.199763656356510.1055/s‑2006‑957768 9434615
     [Google Scholar]
  28. NowakA. KojderK. Zielonka-BrzezickaJ. The use of Ginkgo biloba L. as a neuroprotective agent in the Alzheimer’s disease.Front. Pharmacol.20211277503410.3389/fphar.2021.775034 34803717
     [Google Scholar]
  29. GuanL. YangH. CaiY. ADMET-score - A comprehensive scoring function for evaluation of chemical drug-likeness.MedChemComm201910114815710.1039/C8MD00472B 30774861
     [Google Scholar]
  30. RaulinA.C. DossS.V. TrottierZ.A. IkezuT.C. BuG. LiuC.C. ApoE in Alzheimer’s disease: Pathophysiology and therapeutic strategies.Mol. Neurodegener.20221717210.1186/s13024‑022‑00574‑4 36348357
     [Google Scholar]
  31. YamazakiY. PainterM.M. BuG. KanekiyoT. Apolipoprotein E as a therapeutic target in Alzheimer’s disease: A review of basic research and clinical evidence.CNS Drugs201630977378910.1007/s40263‑016‑0361‑4 27328687
     [Google Scholar]
  32. ShiC. LiuJ. WuF. YewD. Ginkgo biloba extract in Alzheimer’s disease: From action mechanisms to medical practice.Int. J. Mol. Sci.201011110712310.3390/ijms11010107 20162004
     [Google Scholar]
  33. ArafahA. KhatoonS. RasoolI. The future of precision medicine in the cure of Alzheimer’s disease.Biomedicines202311233510.3390/biomedicines11020335 36830872
     [Google Scholar]
  34. SinghS.K. SrivastavS. CastellaniR.J. Plascencia-VillaG. PerryG. Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD and other neurological disorders.Neurotherapeutics201916366667410.1007/s13311‑019‑00767‑8 31376068
     [Google Scholar]
  35. KimS. ThiessenP.A. BoltonE.E. PubChem substance and compound databases.Nucleic Acids Res.201644D1D1202D121310.1093/nar/gkv951 26400175
     [Google Scholar]
  36. WebbB SaliA Comparative protein structure modeling using MODELLER.Curr Protoc Bioinform2016545.6.15.6.3710.1002/cpbi.327322406
     [Google Scholar]
  37. ChenY. ZhangH. WangW. ShenY. PingZ. Rapid generation of high-quality structure figures for publication with PyMOL-PUB.Bioinformatics2024403btae13910.1093/bioinformatics/btae139 38449297
     [Google Scholar]
  38. GuexN. PeitschM.C. SWISS‐MODEL and the swiss‐Pdb viewer: An environment for comparative protein modeling.Electrophoresis199718152714272310.1002/elps.1150181505 9504803
     [Google Scholar]
  39. BurleyS.K. BermanH.M. KleywegtG.J. MarkleyJ.L. NakamuraH. VelankarS. Protein data bank (PDB): The single global macromolecular structure archive.Methods Mol. Biol.2017160762764110.1007/978‑1‑4939‑7000‑1_26 28573592
     [Google Scholar]
  40. SahuN. MadanS. WaliaR. Multi-target mechanism of Solanum xanthocarpum for treatment of psoriasis based on network pharmacology and molecular docking.Saudi Pharm. J.2023311110178810.1016/j.jsps.2023.101788 37811124
     [Google Scholar]
  41. PiresD.E.V. BlundellT.L. AscherD.B. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures.J. Med. Chem.20155894066407210.1021/acs.jmedchem.5b00104 25860834
     [Google Scholar]
  42. DhawanA. SharmaV. Toxicity assessment of nanomaterials: Methods and challenges.Anal. Bioanal. Chem.2010398258960510.1007/s00216‑010‑3996‑x 20652549
     [Google Scholar]
  43. TrottO. OlsonA.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.J. Comput. Chem.201031245546110.1002/jcc.21334 19499576
     [Google Scholar]
  44. PettersenE.F. GoddardT.D. HuangC.C. UCSF Chimera — A visualization system for exploratory research and analysis.J. Comput. Chem.200425131605161210.1002/jcc.20084 15264254
     [Google Scholar]
  45. YasirM. ParkJ. HanE.T. Discovery of novel TACE inhibitors using graph convolutional network, molecular docking, molecular dynamics simulation, and biological evaluation.PLoS One20241912e031524510.1371/journal.pone.0315245 39729480
     [Google Scholar]
  46. HollingsworthS.A. DrorR.O. Molecular dynamics simulation for all.Neuron20189961129114310.1016/j.neuron.2018.08.011 30236283
     [Google Scholar]
  47. KinneyJ.W. BemillerS.M. MurtishawA.S. LeisgangA.M. SalazarA.M. LambB.T. Inflammation as a central mechanism in Alzheimer’s disease.Alzheimers Dement.20184157559010.1016/j.trci.2018.06.014 30406177
     [Google Scholar]
  48. SallowayS.P. SevingyJ. BudurK. Advancing combination therapy for Alzheimer’s disease.Alzheimers Dement.202061e1207310.1002/trc2.12073 33043108
     [Google Scholar]
  49. GoldbergT.E. HueyE.D. DevanandD.P. Association of APOE e2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies.Nat. Commun.2020111472710.1038/s41467‑020‑18198‑x 32948752
     [Google Scholar]
  50. PalleriaC. Di PaoloA. GiofrèC. Pharmacokinetic drug-drug interaction and their implication in clinical management.J. Res. Med. Sci.2013187601610 24516494
     [Google Scholar]
  51. GarbettN.C. ChairesJ.B. Thermodynamic studies for drug design and screening.Expert Opin. Drug Discov.20127429931410.1517/17460441.2012.666235 22458502
     [Google Scholar]
  52. MiculasD.C. NegruP.A. BungauS.G. BehlT. HassanS.S. TitD.M. Pharmacotherapy evolution in Alzheimer’s disease: Current framework and relevant directions.Cells202212113110.3390/cells12010131 36611925
     [Google Scholar]
  53. LiuQ JinZ XuZ Antioxidant effects of Ginkgolides and bilobalide against cerebral ischemia injury by activating the Akt/Nrf2 pathway in vitro and in vivo.20192424415210.1007/s12192‑019‑00977‑130815818
     [Google Scholar]
  54. MazzantiG. Di GiacomoS. Curcumin and resveratrol in the management of cognitive disorders: What is the clinical evidence?Molecules2016219124310.3390/molecules21091243 27649135
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128386836250723134001
Loading
Ginkgolide as a Promising Multi-Target Therapeutic for Alzheimer's Disease: Targeting ApoE4 and Beyond
Curr. Pharm. Des. 32, 1200 (2026); https://doi.org/10.2174/0113816128386836250723134001
/content/journals/cpd/10.2174/0113816128386836250723134001
/content/journals/cpd/10.2174/0113816128386836250723134001
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Alzheimer's disease; apolipoprotein E4 (ApoE4); blood-brain barrier; Ginkgolide; molecular docking; multi-target therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test